Migraine

 
Fremanezumab Demonstrates Dual Benefits in Adults with Migraine and Depression
May 06, 2025

New data from UNITE study suggest fremanezumab was effective in alleviating migraine and comorbid MDD in patients with both conditions.

FDA Approves STS101 (Dihydroergotamine) Nasal Powder for Acute Treatment of Migraine
May 01, 2025

The only approved DHE nasal powder addresses persistent limitations of existing DHE formulations, including liquid nasal sprays and injectables, Satsuma stated.

Switching Anti-CGRP Monoclonal Antibody Therapy in Nonresponders with Migraine May Reduce Monthly Headache Days
April 29, 2025

Subgroup analyses found no significant difference in efficacy based on change in therapeutic action (ie, CGRP vs its receptor), doses, or intertreatment interval.

FDA Grants First-in-Class Marketing Authorization for Digital Therapeutic in Episodic Migraine Prevention
April 16, 2025

CT-132 is a 12-week app-based intervention that uses validated behavioral techniques to modulate labile brain circuitry involved in migraine, according to Click Therapeutics.

Zonisamide Shows Promise for Hard-to-Treat Migraine in Children, Adolescents
February 27, 2025

While the data on zonisamide efficacy for migraine in youths is preliminary, all study participants experienced a 66% reduction in headaches after 1 month of treatment.

Symbravo for Migraine Demonstrates Efficacy Superior to Prior CGRP Inhibitor Treatment in Phase 3 Trial
February 25, 2025

Symbravo, compared with previous CGRP inhibitor therapy, achieved superior response across efficacy measures including pain freedom and improvements in QoL.

Headaches and Suicide
February 10, 2025

The risk of a suicide attempt was 2 times greater among those with headache, across types including tension type headache, migraine, trigeminal autonomic cephalalgia, and posttraumatic headache.

FDA Greenlights Symbravo for Acute Treatment of Migraine: Daily Dose
February 06, 2025

Your daily dose of the clinical news you may have missed.

New ACP Guidelines on Prevention of Episodic Migraine Cite Lack of Comparative Evidence for Treatments
February 05, 2025

Pharmacologic treatment to prevent episodic migraine should follow a sequential trial approach that considers medication cost, headache triggers, adherence, and lifestyle interventions.

Symbravo Mechanism of Action and Patient Selection, with PI Stewart Tepper, MD
February 04, 2025

Tepper, principal investigator for phase 3 trials of Symbravo as acute treatment for migraine in adults, reviews the new drug's dual MOA and target patient populations.